The 2018 PSI Conference took place at the Beurs Van Berlage, Amsterdam, from 3rd to 6th June 2018. The theme for the conference was “Breaking Boundaries in Drug Development”.

The conference consisted of a variety of plenary and parallel sessions, as well as breakout discussion sessions, a poster session and the Annual General Meeting. Sessions included data transparency, the Asterix project in rare diseases, application and implementation of methodologies in statistics, missing data, study design role play, regulatory town hall and many more, with speakers from industry, academia and regulatory agencies.

Scientific Programme

Please click here to view the full programme from the 2018 conference. 


Please click here to view the poster abstracts presented at the 2018 conference. 


Lucy Rowell
PSI Conference Chair

_DSC4964 _DSC5283 _DSC5231 DSC_4219 _DSC5186 _DSC5342 _DSC5211 _DSC5252 _DSC5298 _DSC4897 _DSC5345 _DSC5354 _DSC5397 _DSC5455 _DSC5138 _DSC5560 _DSC5651 DSC_3494 DSC_3526 DSC_3582 DSC_3594 DSC_3601 _DSC5062 DSC_3830 DSC_3797 DSC_3846 DSC_3905 DSC_3930 DSC_4296 DSC_4008 DSC_4051 DSC_3822 DSC_4152 DSC_4289-2 _DSC4956 DSC_4352-2 _DSC5075 DSC_4136 _DSC5108 _DSC5546

EventsFuture Events

  • PSI Webinar: Adaptive design: updated draft FDA guidance and its implications - Dates: 04 – 04 Jul, 2019

    In September 2018 the FDA published a guidance on adaptive design for clinical trials of drugs and biologics, updating (not finalizing) its initial draft from February 2010. The main focus of the webinar will be to provide an overview of its main contents, which will be presented by Jürgen Hummel (PPD). In addition, Kaspar Rufibach (Roche) will introduce an open-source statistical software for adaptive designs, RPACT (an R package that enables the design and analysis of confirmatory adaptive clinical trials). Kit Roes will also comment on the guidance from a European Regulatory perspective, which will be followed by a brief panel discussion.
  • PSI One day Scientific meeting, South West: Designing and Analysing Adaptive Trial Design Studies - Dates: 24 – 24 Jun, 2019

    During this meeting we will hear about adaptive sample allocation for phase II/III designs, a new CONSORT extension reporting guideline for adaptive designs, regulatory aspects and case studies.
Costello Logo_RGB JPG

Statistics at Costello Medical


Pharm Research Associates

Principal Biostatistician


Autolus Therapeutics

Head of Statistical and Data Innovation as Head of Biometrics



Leading Biostatistician with experience in Big Data and advanced analytics



Biostatistician with experience in clinical drug development



Statistician Opportunities in the UK